| Document |
Document Title |
|
WO/2019/073433A1 |
Combination of dry extract of Rhodiola, dry extract of Tribulus terrestris, dry extract of Undaria pinnatifida, Moringa oleifera, folic acid and vitamin B12 in the form of food supplement for mitigating woman's disorders caused by ageing.
|
|
WO/2019/073999A1 |
A purification system for an intracellular fluid, said system comprising: an aseptic room; a conveyance device conveying a first container in which a cell-containing solution is housed; a cell membrane disruption device disrupting cell m...
|
|
WO/2019/069981A1 |
Provided is a material that improves menopausal symptoms such as hot flashes. An oral hot-flash ameliorant having a chlorogenic acid as an active ingredient. An oral hot-flash ameliorant having, as an active ingredient, a coffee bean ext...
|
|
WO/2019/061648A1 |
The present invention provides a polypeptide targeting placental chondroitin sulfate A, a targeted delivery system targeting placental chondroitin sulfate A, and a preparation method. The polypeptide and targeted delivery system provided...
|
|
WO/2019/056070A1 |
The present invention relates to relates to methods and products for improving the quality of sperm, methods for treating subjects to improve sperm quality or improve fertility, and use of sperm with improved quality in assisted reproduc...
|
|
WO/2019/059863A1 |
The present invention is related to a pharmaceutical formulation in a tablet form comprising Ulipristal Acetate as an active agent and at least one excipient in a unit tablet, for being used in an emergency contraception after sexual int...
|
|
WO/2019/057709A1 |
The present invention relates i.a. to compositions which are suitable for treatment of infertility or subfertility, in particular infertility or subfertility caused by polycystic ovary syndrome (PCOS)or anovulation, or which are suitable...
|
|
WO/2019/051540A1 |
The disclosure relates generally to methods and reagents for reducing or shutting down lactation in a non-human mammalian subject. In particular, the disclosure relates to a method of reducing or shutting down lactation in a non-human ma...
|
|
WO/2019/049933A1 |
Provided are novel peptides. These peptides specifically inhibit activity of proteases which include an amino acid sequence expressed by SEQ ID NO: 23 and have a target molecule.
|
|
WO/2019/049081A1 |
The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml or about 160 mg/ml to 240 mg/ml medroxyprogesterone acetate, 1.2 mg/ml to 3.0 mg/ml docusate sodiu...
|
|
WO/2019/046582A1 |
Testosterone ester triglyceride formulations, optionally further including adducts. Methods of in-situ control of the manufacture or formation of such adducts are also described.
|
|
WO/2019/045075A1 |
To provide a therapeutic agent for endometriosis and adenomyosis. IL-33 was identified as an exacerbating factor in endometriosis and adenomyosis, and an IL-33 antagonist, which is capable of inhibiting the function of IL-33, was found t...
|
|
WO/2019/041078A1 |
The present application discloses, among other things, asymmetric synthesis a diastereomeric compound of formula (I) (e.g., α-anordrin) or salt thereof. Also provided are methods and compositions for treatment of estrogen deficiency as ...
|
|
WO/2019/042934A1 |
The invention relates to a composition for use in the treatment and/or prevention of infertility. The invention is characterised in that the composition comprises a pollen extract and/or a pistil extract, said pollen and/or pistil being ...
|
|
WO/2019/042192A1 |
The present application discloses, among other things, asymmetric synthesis a diastereomeric compound of formula (I) (e.g., α-anordrin) or salt thereof. Also provided are methods and compositions for treatment of estrogen deficiency as ...
|
|
WO/2019/043143A1 |
Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility in patients having high AMH and low bodyweight.
|
|
WO/2019/039540A1 |
The present invention pertains to: a cytocidal agent which comprises a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 and a site capable of selectively binding to a target molecule; and the cytocidal agent wherein...
|
|
WO/2019/040230A1 |
Methods of treating genital psoriasis, genital pruritus and genital psoriasis sexual activity impairment with anti-IL17A antibodies, including dose regimens and pharmaceutical formulations of anti-IL17A antibodies for use in the treatmen...
|
|
WO/2019/034696A1 |
The present invention relates to compounds of formula (I): Formula (I) wherein Q is selected from O or S; L is a saturated or unsaturated, optionally substituted C1-C12 hydrocarbylene group optionally including one or more heteroatoms N,...
|
|
WO/2019/034688A1 |
The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl group substituted with an amide-containing group. The present invention further relates to salts, solvates and prodrugs of such compo...
|
|
WO/2019/034878A1 |
There is described a composition for topical application to the penis for treatment of erectile dysfunction, the composition comprising glyceryl trinitrate (GTN) as active ingredient dissolved in a blend of volatile and non- volatile sol...
|
|
WO/2019/036367A1 |
A method for preventing and/or treating fibrosis associated with a reproductive tract or digestive tract disease or disorder includes administering an effective amount of a multikinase inhibitor to an animal or human in need thereof. The...
|
|
WO/2019/032946A1 |
A method of manufacturing oxytocin or oxytocin receptor agonist comprising a step of combining an antisolvent with a solution comprising oxytocin or oxytocin receptor agonist so as to precipitate a product oxytocin or a product oxytocin ...
|
|
WO/2019/023748A1 |
The present invention relates to a method of increasing fertility, or reducing rate of decline in fertility, or restoring fertility, of a female subject, comprising administering to the subject an effective amount of an agent which eleva...
|
|
WO/2019/026016A1 |
A pharmaceutical composition or food supplement is disclosed that is effective in the treatment and the prevention of male sexual disorders such as erectile dysfunction and the decrease in sexual desire, comprising the synergic combinati...
|
|
WO/2019/024249A1 |
A placental extract biological gel preparation for treating premature ovarian failure, and a method of preparing same. The placental extract biological gel preparation is obtained from a gel base and placental extract, said extract servi...
|
|
WO/2019/024250A1 |
A placental extract and a preparation method therefor. The preparation method comprises: freezing placental tissue, extracting effective ingredients, and purifying said ingredients to obtain the final product. The placental extract may b...
|
|
WO/2019/028034A1 |
Enfumafungin derivative triterpenoid antifungal compounds are used to treat or prevent fungal infections occurring in or under acidic conditions where the pH is lower than about 7, due to their unexpected, enhanced efficacy under such co...
|
|
WO/2019/027009A1 |
The present invention provides a nucleic acid complex represented by formula 1, the nucleic acid complex being capable of suppressing the expression of β2GPI. Formula 1: (in formula 1, X is a double-stranded nucleic acid that comprises ...
|
|
WO/2019/028185A1 |
In some aspects, the disclosure relates to methods for screening clinical samples for the presence of L-form bacteria associated with endometriosis and/or ovarian fibroid tumors. The disclosure is based, in part, on screening methods use...
|
|
WO/2019/020102A1 |
The present invention relates to a method for preparing a pyrimidone heteroaryl derivative and an intermediate of the pyrimidone heteroaryl derivative. Specifically, in the present invention, the pyrimidone heteroaryl derivative is prepa...
|
|
WO/2019/020367A1 |
The present invention relates to a composition comprising a dequalinium salt, maltodextrin and lactic acid for application in the treatment of the bacterial vaginosis. The inventor proposes an improved therapeutic strategy based on the a...
|
|
WO/2019/023471A1 |
The present invention includes compositions and methods preventing or reversing the symptoms of aging in a subject in need thereof comprising administering to the subject an amount of a composition comprising pterostilbene, nicotinamide,...
|
|
WO/2019/015085A1 |
A traditional Chinese medicine for treating amenorrhea is prepared from the following medicinal materials in parts by weight: 15 parts of Semen Cuscutae, 10 parts of Fructus Rubi, 15 parts of Fructus Lycii, 10 parts of Fructus Schisandra...
|
|
WO/2019/015083A1 |
A traditional Chinese medicine for treating cervical erosion is prepared from the following raw materials in parts by weight: 15 parts of Cortex Phellodendri, 15 parts of Radix Sophorae Flavescentis, 15 parts of Fructus Cnidii, 15 parts ...
|
|
WO/2019/016555A1 |
Novel peptides and the uses thereof, in particular for use in male contraception or for use in the treatment of male infertility.
|
|
WO/2019/018348A1 |
Ammonia oxidizing microorganism preparations for delivery to the urogenital system, kits including ammonia oxidizing preparations for delivery to the urogenital system, and devices for administering ammonia oxidizing preparations to the ...
|
|
WO/2019/016074A1 |
The present disclosure relates to new therapeutic uses of MPO inhibitors and methods of treatment involving the same.
|
|
WO/2019/017384A1 |
The present invention provides a peptide having a structure in which a portion of a dominant-negative peptide of BIG3 which inhibits interaction between BIG3 and PHB2, is replaced by at least two stapling structures. The peptide accordin...
|
|
WO/2019/013637A1 |
The present invention relates to a mixture of strains of Lactobacillus crispatus, which mixture comprises strains that have a different carbohydrate degradation profile, comprising at least one strain of L. crispatus that is able to degr...
|
|
WO/2019/012199A1 |
The food supplement according to the present invention for protecting female and male fertility intended for oral administration, helping reduce both oxygenated free radicals, which cause DNA damage, and homocystine, therefore reducing t...
|
|
WO/2019/009739A1 |
The invention relates to application of totarol for production of a preparation for treatment of vaginal mucous membrane inflammations of bacterial origin, for alleviation of symptoms in such a treatment, and for prophylaxis and preventi...
|
|
WO/2019/007299A1 |
Disclosed are a salt and a polymorph of a benzopyrimidinone compound and a pharmaceutical composition and the use thereof. In particular, disclosed are a hydrochloride of a benzopyrimidinone compound as shown in the following formula, (I...
|
|
WO/2019/008025A1 |
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...
|
|
WO/2019/004877A1 |
The group of inventions relates to medicine and veterinary science, and more particularly to medical and veterinary gynaecology. Proposed is the use of 9-phenyl-sym-octahydroselenoxanthene as an agent for treating female infertility and ...
|
|
WO/2019/003053A1 |
The present invention relates to an association comprising molecular oxygen and hyaluronic acid for use in the topical treatment of vaginal disorders and, more preferably, for the treatment of vaginal dryness and vulvovaginal atrophy.
|
|
WO/2019/000504A1 |
Provided are a PDE 5 and a preparation method therefor, and application of the PDE 5 to preparation of drugs used for treating, alleviating or preventing PDE 5-related diseases or disease states of mammals. The structural formula of the ...
|
|
WO/2018/236680A1 |
Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using isolated populations of mesenchymal stem cells are disclosed.
|
|
WO/2018/233728A1 |
Provided in the present application are benzo[d]isoxazole compounds, a preparation method therefor and an application thereof. The benzo[d]isoxazole compounds are a group of compounds having novel structures and which act as bromodomain ...
|
|
WO/2018/234342A1 |
Compounds of Formula (0), and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
|
